Nanobiotix Sa - Adr (NBTX)
$5.22
+0.11
(+2.1%)▲
Performance
- $4.98$5.35$5.22
4.68%
Downside
Day's Volatility :6.99%
Upside
2.43%
- $4.14$8.96$5.22
20.69%
Downside
52 Weeks Volatility :53.8%
Upside
41.75%
Returns
| Period | Nanobiotix Sa - Adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -2.76% | 4.7% | 0.0% |
6 Months | -14.98% | 5.9% | 0.0% |
1 Year | -18.63% | 16.3% | 0.0% |
3 Years | -55.68% | 19.6% | -20.8% |
Highlights
Market Capitalization | 247.3M |
Book Value | - $0.46 |
Earnings Per Share (EPS) | -0.81 |
Wall Street Target Price | 11.13 |
Profit Margin | -79.31% |
Operating Margin TTM | -253.32% |
Return On Assets TTM | -22.02% |
Return On Equity TTM | -198.69% |
Revenue TTM | 42.2M |
Revenue Per Share TTM | 0.98 |
Quarterly Revenue Growth YOY | 182.1% |
Gross Profit TTM | 4.8M |
EBITDA | -22.3M |
Diluted Eps TTM | -0.81 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 113.22%
Company Financials
| FY18 | Y/Y Change | |
|---|---|---|
Revenue | 132.0K | ↓ 53.96% |
Net Income | -34.0M | ↑ 14.35% |
Net Profit Margin | -25.8K% | ↓ 15396.79% |
| FY19 | Y/Y Change | |
|---|---|---|
Revenue | 75.6K | ↓ 41.38% |
Net Income | -56.6M | ↑ 70.31% |
Net Profit Margin | -74.9K% | ↓ 49102.59% |
| FY20 | Y/Y Change | |
|---|---|---|
Revenue | 60.8K | ↓ 26.47% |
Net Income | -40.9M | ↓ 33.96% |
Net Profit Margin | -67.2K% | ↑ 7629.0% |
| FY21 | Y/Y Change | |
|---|---|---|
Revenue | 11.3K | ↓ 80.0% |
Net Income | -53.1M | ↑ 39.8% |
Net Profit Margin | -470.0K% | ↓ 402794.0% |
| FY22 | Y/Y Change | |
|---|---|---|
Revenue | 5.1M | ↑ 47660.0% |
Net Income | -60.4M | ↑ 21.36% |
Net Profit Margin | -1.2K% | ↑ 468845.63% |
| FY23 | Y/Y Change | |
|---|---|---|
Revenue | 32.8M | ↑ 529.36% |
Net Income | -43.3M | ↓ 30.4% |
Net Profit Margin | -132.08% | ↑ 1062.29% |
| Q3 FY22 | Q/Q Change | |
|---|---|---|
Revenue | 1.7M | ↑ 159.37% |
Net Income | -15.2M | ↓ 41.79% |
Net Profit Margin | -890.17% | ↑ 3076.27% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 1.8M | - |
Net Income | -15.0M | - |
Net Profit Margin | -853.29% | - |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 1.8M | ↑ 0.0% |
Net Income | -30.5M | ↑ 100.0% |
Net Profit Margin | -1.7K% | ↓ 853.3% |
| Q3 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 16.5M | ↑ 899.54% |
Net Income | -5.8M | ↓ 79.36% |
Net Profit Margin | -35.25% | ↑ 1671.34% |
| Q1 FY24 | Q/Q Change | |
|---|---|---|
Revenue | 16.5M | ↑ 0.0% |
Net Income | -5.8M | ↑ 0.0% |
Net Profit Margin | -35.25% | ↑ 0.0% |
| FY18 | Y/Y Change | |
|---|---|---|
Total Assets | 52.5M | ↓ 19.61% |
Total Liabilities | 36.3M | ↑ 135.9% |
| FY19 | Y/Y Change | |
|---|---|---|
Total Assets | 62.5M | ↑ 21.67% |
Total Liabilities | 64.6M | ↑ 81.88% |
| FY20 | Y/Y Change | |
|---|---|---|
Total Assets | 163.0M | ↑ 138.47% |
Total Liabilities | 77.3M | ↑ 9.37% |
| FY21 | Y/Y Change | |
|---|---|---|
Total Assets | 115.0M | ↓ 24.07% |
Total Liabilities | 84.8M | ↑ 17.96% |
| FY22 | Y/Y Change | |
|---|---|---|
Total Assets | 63.3M | ↓ 41.27% |
Total Liabilities | 91.9M | ↑ 15.78% |
| FY23 | Y/Y Change | |
|---|---|---|
Total Assets | 102.4M | ↑ 57.1% |
Total Liabilities | 104.4M | ↑ 10.28% |
| Q4 FY22 | Q/Q Change | |
|---|---|---|
Total Assets | 63.3M | ↑ 0.0% |
Total Liabilities | 91.9M | ↑ 0.0% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 43.2M | ↓ 32.39% |
Total Liabilities | 100.8M | ↑ 8.5% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 43.8M | ↑ 0.0% |
Total Liabilities | 102.2M | ↑ 0.0% |
| Q3 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 93.9M | ↑ 132.38% |
Total Liabilities | 95.7M | ↑ 1.64% |
| Q4 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 102.4M | ↑ 0.0% |
Total Liabilities | 104.4M | ↑ 0.0% |
| Q1 FY24 | Q/Q Change | |
|---|---|---|
Total Assets | 93.9M | ↑ 0.0% |
Total Liabilities | 95.7M | ↑ 0.0% |
| FY18 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -29.6M | ↑ 23.55% |
Investing Cash Flow | 80.8K | ↓ 104.54% |
Financing Cash Flow | 16.9M | ↓ 69.4% |
| FY19 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -45.7M | ↑ 58.43% |
Investing Cash Flow | -1.6M | ↓ 2154.93% |
Financing Cash Flow | 46.1M | ↑ 179.39% |
| FY20 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -33.5M | ↓ 33.11% |
Investing Cash Flow | -136.2K | ↓ 92.32% |
Financing Cash Flow | 135.9M | ↑ 169.39% |
| FY21 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -33.8M | ↑ 8.48% |
Investing Cash Flow | -273.6K | ↑ 116.07% |
Financing Cash Flow | -5.9M | ↓ 104.63% |
| FY22 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -39.3M | ↑ 24.21% |
Investing Cash Flow | 146.0K | ↓ 157.02% |
Financing Cash Flow | -6.0M | ↑ 9.09% |
| Q3 FY22 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | -9.7M | ↓ 45.22% |
Investing Cash Flow | 42.1K | ↑ 60.38% |
Financing Cash Flow | -1.1M | ↓ 65.92% |
| Q4 FY22 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | -10.4M | ↑ 0.01% |
Investing Cash Flow | 45.0K | ↑ 0.0% |
Financing Cash Flow | -1.1M | ↑ 0.0% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | -9.2M | ↓ 11.8% |
Investing Cash Flow | -175.0K | ↓ 484.71% |
Financing Cash Flow | -1.1M | ↓ 0.33% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | -19.1M | ↑ 103.48% |
Investing Cash Flow | -177.4K | ↑ 0.0% |
Financing Cash Flow | -2.0M | ↑ 71.84% |
Technicals Summary
Sell
Neutral
Buy
Nanobiotix Sa - Adr is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nanobiotix Sa - Adr | -0.2% | -14.98% | -18.63% | -55.68% | -64.71% |
 Regeneron Pharmaceuticals, Inc. | -12.19% | 6.5% | 20.85% | 84.03% | 245.65% |
 Novo Nordisk A/s | -11.15% | -6.13% | 27.31% | 138.21% | 354.53% |
 Alnylam Pharmaceuticals, Inc. | 5.38% | 73.95% | 61.12% | 32.59% | 252.19% |
 Vertex Pharmaceuticals Incorporated | -2.58% | 13.46% | 29.21% | 155.56% | 172.0% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nanobiotix Sa - Adr | NA | NA | NA | 0.0 | -1.99 | -0.22 | NA | -0.46 |
Regeneron Pharmaceuticals, Inc. | 26.37 | 26.37 | 1.36 | 45.03 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.54 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nanobiotix Sa - Adr | Buy | $246.0M | -64.71% | NA | -79.31% |
Regeneron Pharmaceuticals, Inc. | Buy | $109.8B | 245.65% | 26.37 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 354.53% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.2B | 252.19% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $115.8B | 172.0% | 32.84 | -4.74% |
Insights on Nanobiotix Sa - Adr
Increasing Revenue
Revenue is up for the last 3 quarters, 1.64M → 16.45M (in $), with an average increase of 45.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -28.09M → -5.80M (in $), with an average increase of 192.2% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.1% return, outperforming this stock by 78.0%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 89.8%
Institutional Holdings
Johnson & Johnson
11.86%Baillie Gifford & Co Limited.
6.05%Perceptive Advisors LLC
1.17%BlackRock Inc
0.50%UBS Group AG
0.01%
Company Information
nanobiotix (euronext: nano / isin: fr0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. the company’s first-in-class, proprietary technology, nanoxray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. nanoxray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. nbtxr3 is being evaluated in: soft tissue sarcoma (sts), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). additionally, head and neck cancer and rectal cancer trials led by nanobiotix’s taiwanese partner, pharmaengine, are underway in the asia pacific region. the company started a new preclinical research program in immuno-oncology with its lea
Organization | Nanobiotix Sa - Adr |
Employees | 110 |
CEO | Mr. Laurent Levy Ph.D. |
Industry | Healthcare |
